Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06271681
PHASE4

Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

Sponsor: VA Sierra Nevada Health Care System

View on ClinicalTrials.gov

Summary

The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster with of 21-valent pneumococcal conjugate vaccine . Immune response will be assessed by opsonophagocytic assay reactivity.

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2026-01-01

Completion Date

2027-06-01

Last Updated

2025-08-14

Healthy Volunteers

No

Interventions

DRUG

21-valent pneumococcal conjugate vaccine

FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment